FDA says current dose of GSK, Vir COVID therapy likely not effective against BA.2 variant
The FDA’s move comes as a blow to the companies which have seen high demand for Sotrovimab after it became one of the few COVID-19…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Vir Biotechnology
Drugmakers and scientists begin hunt for long COVID treatments
Researchers, biotech companies and public health experts say major pharma companies are integral to getting a proven treatment for…
Vir Biotechnology announces maiden marketing authorisation for sotrovimab in Australia
As part of its overarching effort to address COVID-19, the Australian Government recently announced an agreement to purchase…
Vir, GSK to seek EUA for COVID-19 antibody therapy
Vir and GSK also said that a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, South…
Vir Biotech research highlights mechanism to enhance monoclonal antibodies for inducing protective…
The research published in Nature focuses on the role of the Fc domain of monoclonal antibodies, regions with the capacity to bind…
Alnylam’s gene-silencing efforts get $2 billion Blackstone backing
Alnylam is the first drugmaker to win US approval for a treatment using the Nobel prize-winning RNA interference (RNAi) technology…